Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of α-fetoprotein

Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of α-fetoprotein

Abstract Anlotinib, a novel multi-targeting tyrosine kinase inhibitor (TKI), has been investigated in a variety of malignant tumors. This retrospective study was designed to investigate the efficacy and safety of anlotinib as first- or second-line therapy for advanced or metastatic hepatocellular ca...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianping Chang, Bowen Xu, Zhiyu Li, Zhicheng Wei, Xu Che, Jianqiang Cai, Yanjiang Yin, Xinyu Bi
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Advanced hepatocellular carcinoma
Anlotinib
Tyrosine kinase inhibitor
Α-fetoprotein
Prognostic factor
Predictive factor
Online Access:https://doi.org/10.1038/s41598-025-14759-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items